Details
| Translated title of the contribution | Modern therapeutic stategies for the management of lupus nephritis |
|---|---|
| Original language | German |
| Pages (from-to) | 70-80 |
| Number of pages | 11 |
| Journal | Nieren- und Hochdruckkrankheiten |
| Volume | 33 |
| Issue number | 2 |
| Publication status | Published - Feb 2004 |
| Externally published | Yes |
Abstract
The manifestation of lupus nephritis determines the prognosis of progressing systemic lupus erythematodes. In its proliferative forms, lupus nephritis has to be treated. Cyclophosphamid still represents the standard therapy, but depending on the dosage it is associated with severe side effects and frequent secondary infections. New therapeutic concepts try to achieve a dose reduction by the early use of azathioprin as sequential therapy. In our observation study of 5 patients in remission, 1 patient resistant to therapy and 2 patients with newly diagnosed lupus nephritis under steroids, the alternative drug mycophenolate mofetil led to a stabilisation of kidney function and proteinuria. The paper deals with the effectiveness of this modern immunosuppressive compared to established substances like cyclosporine and relating to literature. An overview of other available therapeutic means is given. Some of them like immunoadsorption can only be used additionally to a immunosuppressive drug regimen. Future prospects of modern lupus therapy are highlighted.
ASJC Scopus subject areas
- Medicine(all)
- Internal Medicine
- Medicine(all)
- Nephrology
Cite this
- Standard
- Harvard
- Apa
- Vancouver
- BibTeX
- RIS
In: Nieren- und Hochdruckkrankheiten, Vol. 33, No. 2, 02.2004, p. 70-80.
Research output: Contribution to journal › Review article › Research › peer review
}
TY - JOUR
T1 - Aktuelle therapeutische Strategien im Management der Lupusnephritis
AU - Blume, Cornelia
AU - Ivens, Katrin
AU - Helmchen, Udo
AU - Grabensee, B.
PY - 2004/2
Y1 - 2004/2
N2 - The manifestation of lupus nephritis determines the prognosis of progressing systemic lupus erythematodes. In its proliferative forms, lupus nephritis has to be treated. Cyclophosphamid still represents the standard therapy, but depending on the dosage it is associated with severe side effects and frequent secondary infections. New therapeutic concepts try to achieve a dose reduction by the early use of azathioprin as sequential therapy. In our observation study of 5 patients in remission, 1 patient resistant to therapy and 2 patients with newly diagnosed lupus nephritis under steroids, the alternative drug mycophenolate mofetil led to a stabilisation of kidney function and proteinuria. The paper deals with the effectiveness of this modern immunosuppressive compared to established substances like cyclosporine and relating to literature. An overview of other available therapeutic means is given. Some of them like immunoadsorption can only be used additionally to a immunosuppressive drug regimen. Future prospects of modern lupus therapy are highlighted.
AB - The manifestation of lupus nephritis determines the prognosis of progressing systemic lupus erythematodes. In its proliferative forms, lupus nephritis has to be treated. Cyclophosphamid still represents the standard therapy, but depending on the dosage it is associated with severe side effects and frequent secondary infections. New therapeutic concepts try to achieve a dose reduction by the early use of azathioprin as sequential therapy. In our observation study of 5 patients in remission, 1 patient resistant to therapy and 2 patients with newly diagnosed lupus nephritis under steroids, the alternative drug mycophenolate mofetil led to a stabilisation of kidney function and proteinuria. The paper deals with the effectiveness of this modern immunosuppressive compared to established substances like cyclosporine and relating to literature. An overview of other available therapeutic means is given. Some of them like immunoadsorption can only be used additionally to a immunosuppressive drug regimen. Future prospects of modern lupus therapy are highlighted.
KW - Lupus nephritis
KW - Therapeutic strategies
UR - http://www.scopus.com/inward/record.url?scp=1542376147&partnerID=8YFLogxK
U2 - 10.5414/nhp33070
DO - 10.5414/nhp33070
M3 - Übersichtsarbeit
AN - SCOPUS:1542376147
VL - 33
SP - 70
EP - 80
JO - Nieren- und Hochdruckkrankheiten
JF - Nieren- und Hochdruckkrankheiten
SN - 0300-5224
IS - 2
ER -